ERBB2 and breast cancer: The RxPONDER study accrued patients with estrogen receptor and/or progesterone receptor positive (>1%), HER2 negative breast cancers with 1-3 positive lymph nodes, and an Oncotype DX (Exact Sciences, Redwood City, CA) score of 0–25.